Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: From the Danish 'MALOVA' ovarian cancer study

APMIS

Volumn 120, Issue 10, 2012, Pages 846-854

  Heeran, Mel C ^a   Høgdall, Claus K ^a   Kjaer, Susanne K ^a,b   Christensen, Lise ^a   Blaakaer, Jan ^c   Christensen, Ib Jarle ^a   Hogdall, Estrid V S ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cyclin E; Immunohistochemistry; Ovarian cancer; Prognosis; Tissue array

Indexed keywords

CYCLIN E;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CYCLIN E; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866157771     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02913.x     Document Type: Article

References (43)

1. Kjaerbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK. Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002 - comparison with other Nordic countries. Acta Obstet Gynecol Scand 2005;84:1006-12.
2. Høgdall CK, Nielsen MLS, Taaning L. Dansk Gynækologisk Cancer Database (DGCD). Årsrapport 2008. København: Lægeforeningens Forlag, 2010.
3. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005;113:977-90.
4. Kjaer SK, Ewertz M. Ovariecancer i Danmark 1943-1982: kræftstatistik nr. 20. Ugeskr Laeger 1987;149:3356-60.
5. Kjaer SK, Storm HH. Female genital organs. Survival of Danish Cancer Patients 1943-87. APMIS 1993;33:107-21.
6. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291-300.
7. Rapkiewicz AV, Espina V, Petricoin EF, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004;40:2604-12.
8. Sant M, Aareleid T, Berrino F, Bielska LM, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003;14(Suppl 5):v61-118.
9. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer; a Gynecologic Oncology Group study. J Clin Oncol 2007;25:5165-71.
10. Hunt T. Cell biology. Cell cycle gets more cyclins. Nature 1991;350:462-3.
11. Nasmyth K. Control of the yeast cell cycle by the Cdc28 protein kinase. Curr Opin Cell Biol 1993;5:166-79.
12. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. BioEssays 1995;17:471-80.
13. 1 cyclins. Cell 1993;73:1059-65.
14. Levine EM. Cell cycling through development. Development 2004;131:2241-6.
15. 1 phase progression: cycling on cue. Cell 1994;79:551-5.
16. Matsumoto Y, Maller JL. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science 2004;306:885-8.
17. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
18. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
19. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999;155:1129-36.
20. Li JQ, Miki H, Ohmori M, Wu F, Funamoto Y. Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol 2001;32:945-53.
21. Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res 2005;11:1447-53.
22. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000;60:242-4.
23. Ferreri AJ, Ponzoni M, Pruneri G, Freschi M, Rossi R, Dell'Oro S, et al. Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int J Cancer 2001;94:599-604.
24. Tissier F, Louvel A, Grabar S, Hagnéré AM, Bertherat J, Vacher-Lavenu MC, et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 2004;150:809-17.
25. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1in breast and cyclin E in ovarian tumors. Int J Cancer 1996;69:247-53.
26. Farley J, Smith LM, Darcy KM, et al. Cyclin E expresion is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 2003;63:1235-41.
27. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106:1925-32.
28. Milde-Langosch K, Hagen M, Bamberger AM, Loning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 2003;22:168-74.
29. Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, et al. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol 2001;32:808-13.
30. Sui L, Dong Y, Ohno M, Sugimoto K, Tai Y, Hando T, et al. Implication of malignancy and prognosis of p27(kip1), cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001;83:56-63.
31. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Platinum-based chemotherapy associated kinase activity predicts response to cyclin E. Clin Cancer Res 2007;13:4800-6.
32. Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, et al. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers 2008;17:585-93.
33. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004;36:295-300.
34. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001;94:1-5.
35. Høgdall EV, Christensen L, Høgdall CK, Frederiksen K, Gayther S, Blaakaer J, et al. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in cancer in ovarian carcinomas. APMIS 2008;116:400-9.
36. Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, et al. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish 'MALOVA' Ovarian Carcinoma Study. Cancer 2003;9:2387-95.
37. Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, et al. Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006;15:798-803.
38. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:187-220.
39. Lee YH, Heo J, Kim TH, Kang H, Kim G, Kim J, et al. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gyn Path 2011;33:205-17.
40. Schmider-Ross A, Pirsig O, Gottschalk E, Denkert C, Lichtenegger W, Reles A. Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J Cancer Res Clin Oncol 2006;132:163-70.
41. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 2004;67:291-9.
42. Blegen H, Einhorn N, Sjovall K, Roschke A, Ghadimi BM, McShane LM, et al. Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer 2000;10:477-87.
43. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004;10:5168-77.